Does Antibody-Dependent Intracellular Neutralization Limit HSV-1 Reactivation?
抗体依赖性细胞内中和是否会限制 HSV-1 重新激活?
基本信息
- 批准号:10573477
- 负责人:
- 金额:$ 20.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-11-10 至 2024-10-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgonistAntibodiesApoptosisBacteriaBindingBlindnessBrainCD8-Positive T-LymphocytesCell Culture TechniquesCell LineageCell NucleusCell membraneCell surfaceCellsCellular MembraneCentral Nervous SystemCommon ColdComplementComplexCytomegalovirusCytoplasmic GranulesCytosolDataElectroporationEquilibriumFc ReceptorGangliaGenetic TranscriptionGranzymeHIVHerpes LabialisHerpes Simplex Virus VaccinesHerpesvirus 1HumanHuman Herpesvirus 2Human Herpesvirus 4ImmuneImmune systemImmunityImmunoglobulin AImmunoglobulin GImmunoglobulin MIn SituIn VitroInduced pluripotent stem cell derived neuronsInfectionLife Cycle StagesLymphocyteLyticMediatingMembrane FusionMicroRNAsModelingMolecularMonitorMucous MembraneNervous SystemNervous System TraumaNeuronsNewborn InfantOrganPeripheral Nervous SystemPrimary InfectionProductionProteinsRecrudescencesRepressionResistanceRoleRouteShelter facilitySimplexvirusStructure of trigeminal ganglionSurfaceTestingTranscriptTranslatingViralViral AntigensViral GenomeVirusVirus LatencyVirus ReplicationVirus Sheddingantiviral immunityarmcytotoxicdesignendosome membraneexperimental studyhuman diseasehuman modelhuman pathogenimmunological synapsein vitro Modelin vivoinhibitorinterestlatency associated transcriptlytic gene expressionmouse modelmulticatalytic endopeptidase complexneuron lossneurotropicpathogenperforinpreventresidenceseropositivestressortau Proteinstherapeutic targetweapons
项目摘要
Antibodies that do not promote the destruction of pathogens in situ or prevent their internalization into target cells
through opsonization are nevertheless key factors in immunity against intracellular pathogens. An important mechanism
by which such “non-neutralizing” antibodies (nNAbs) curtail certain infections has been illuminated by the recent
discovery of antibody-dependent intracellular neutralization (ADIN). In ADIN, cytosolic nNAbs bound to pathogens are
recognized by the intracellular high-affinity Fc receptor Trim21 and the complex is degraded by the proteasome. ADIN
has been found capable of eradicating an enveloped virus. Given that enveloped viruses shed bound antibodies upon cell
membrane fusion, the means by which nNAbs access the cytosol is puzzling. That nNAbs access the cytosol in vivo but not
in vitro suggests that culture models lack a critical cell or factor for nNAb entry.
Herpes simplex viruses (HSV)-1 and -2 initially replicate in a lytic manner at mucosal surfaces but then establish life-
long residence within ganglion neurons of the peripheral nervous system. In neuronal nuclei the viral genome enters
latency, a state of quiescence in which replication is repressed and lytic proteins are produced at near-undetectable levels.
As mature neurons are non-renewable and unchecked viral replication can lead to central nervous system damage, the
control of latency is critical to the host. Ganglia are monitored by CD8+ T-cells, which deliver granzyme B at the
immunological synapse with infected neurons via perforin pores. Cytosolic granzyme B digests ICP4, an essential
transcriptional regulator. The model is therefore that without ICP4 to upregulate transcript production, latency is
perpetuated. Our data show that ICP4 antibodies exist in seropositive human trigeminal ganglia, suggestive of a check on
ICP4 expression by granzyme B and possibly by antibodies to ICP4 that mediate its ADIN.
We hypothesize that antibody-dependent intracellular neutralization of ICP4 limits HSV-1 reactivation. We will
address this in experiments of two Specific Aims: 1) assess whether antibodies gain access to the neuronal cytosol through
the close interaction between CD8+-T-cells and latently-infected neurons; and 2) determine whether non-neutralizing
antibodies direct ADIN of ICP4 produced during latent neuronal infection, stifling viral reactivation. We will use convergent
approaches to benefit from both an in vivo → ex vivo mouse model of human HSV-1 latency, and an in vitro model of
latent HSV-1 infection in human induced pluripotent stem cell-derived neurons. If successful, Aim 1 will define a
heretofore undescribed route of nNAb entry into cells in the context of HSV-1 latency. Aim 2 will elucidate the molecular
basis of the complex balance between viral latency and host immunity. If successful, this R21 study will shift the focus of
HSV vaccine target design to accommodate a role for ADIN in anti-viral immunity, and indicate potential therapeutic
targets including inhibitors of reactivation, or agonists of ADIN. Advances from our studies could also inform far-reaching
approaches to antagonize human pathogens with a latency state including HIV, HCMV, MeV, and EBV.
不促进病原体原位破坏或阻止其内化至靶细胞的抗体
然而,通过调理作用的免疫是对抗细胞内病原体的关键因素。一个重要机制
这种“非中和”抗体(nNAb)通过其减少某些感染已经被最近的研究所阐明。
抗体依赖性细胞内中和(ADIN)的发现。在ADIN中,与病原体结合的胞质nNAb是
该复合物被细胞内高亲和力Fc受体Trim 21识别,并且该复合物被蛋白酶体降解。Adin
已经发现能够根除包膜病毒。鉴于包膜病毒在细胞上释放结合的抗体,
膜融合,nNAb进入胞质溶胶的方式是令人困惑的。nNAb在体内进入胞浆,但不能
表明培养模型缺乏nNAb进入的关键细胞或因子。
单纯疱疹病毒(HSV)-1和-2最初在粘膜表面以裂解方式复制,但随后建立生命-
在周围神经系统的神经节神经元内长期驻留。病毒基因组进入神经细胞核
潜伏期,一种静止状态,其中复制受到抑制,裂解蛋白以几乎检测不到的水平产生。
由于成熟的神经元是不可再生的,不受控制的病毒复制可导致中枢神经系统损伤,
对等待时间的控制对于主机是关键的。神经节由CD 8 + T细胞监测,该细胞在神经节细胞中递送颗粒酶B。
通过穿孔素孔与感染的神经元形成免疫突触。胞浆颗粒酶B抑制ICP 4,一种必需的
转录调节因子因此,该模型是,在没有ICP 4上调转录产物的情况下,潜伏期是
永存我们的数据表明,ICP 4抗体存在于血清阳性的人三叉神经节,提示检查
通过颗粒酶B和可能通过介导其ADIN的ICP 4抗体表达ICP 4。
我们假设ICP 4的抗体依赖性细胞内中和限制了HSV-1的再活化。我们将
在两个特定目的的实验中解决这个问题:1)评估抗体是否通过以下途径进入神经元胞质:
CD 8 +-T细胞和潜伏感染的神经元之间的密切相互作用;以及2)确定非中和性T细胞是否与潜伏感染的神经元之间的相互作用。
抗体指导潜伏性神经元感染期间产生的ICP 4的ADIN,抑制病毒再活化。我们将使用收敛
从人HSV-1潜伏期的体内→离体小鼠模型和人HSV-1潜伏期的体外模型中获益的方法。
人诱导多能干细胞衍生神经元中潜伏HSV-1感染如果成功,目标1将定义一个
迄今为止,在HSV-1潜伏期的背景下,nNAb进入细胞的途径尚未描述。目的2将阐明分子
病毒潜伏期和宿主免疫力之间复杂平衡的基础。如果成功的话,这项R21研究将把重点转移到
HSV疫苗靶向设计以适应ADIN在抗病毒免疫中的作用,并表明潜在的治疗作用
靶点包括再激活抑制剂或ADIN激动剂。我们研究的进展也可以为深远的
拮抗具有潜伏状态的人类病原体包括HIV、HCMV、MeV和EBV的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David A Leib其他文献
David A Leib的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David A Leib', 18)}}的其他基金
Project 3 - Innate immunity and the HSV lytic/latent balance
项目 3 - 先天免疫和 HSV 裂解/潜伏平衡
- 批准号:
10226132 - 财政年份:2013
- 资助金额:
$ 20.5万 - 项目类别:
Project 3 - Innate immunity and the HSV lytic/latent balance
项目 3 - 先天免疫和 HSV 裂解/潜伏平衡
- 批准号:
10460512 - 财政年份:2013
- 资助金额:
$ 20.5万 - 项目类别:
Project 3 - Innate immunity and the HSV lytic/latent balance
项目 3 - 先天免疫和 HSV 裂解/潜伏平衡
- 批准号:
10686369 - 财政年份:2013
- 资助金额:
$ 20.5万 - 项目类别:
Project 3 - Innate immunity and the HSV lytic/latent balance
项目 3 - 先天免疫和 HSV 裂解/潜伏平衡
- 批准号:
9791978 - 财政年份:2013
- 资助金额:
$ 20.5万 - 项目类别:
THE IMPACT OF IRF-3-DEPENDENT MECHANISMS ON THE REPLICATION AND VIRULENCE OF HSV
IRF-3 依赖性机制对 HSV 复制和毒力的影响
- 批准号:
8168325 - 财政年份:2010
- 资助金额:
$ 20.5万 - 项目类别:
Bacterial artificial chromosomes for HSV genomics
用于 HSV 基因组学的细菌人工染色体
- 批准号:
6506060 - 财政年份:2002
- 资助金额:
$ 20.5万 - 项目类别:
Bacterial artificial chromosomes for HSV genomics
用于 HSV 基因组学的细菌人工染色体
- 批准号:
6765969 - 财政年份:2002
- 资助金额:
$ 20.5万 - 项目类别:
Bacterial artificial chromosomes for HSV genomics
用于 HSV 基因组学的细菌人工染色体
- 批准号:
6616809 - 财政年份:2002
- 资助金额:
$ 20.5万 - 项目类别:
HSV INDUCED RNA DEGRADATION AND PATHOGENESIS
HSV 诱导的 RNA 降解和发病机制
- 批准号:
2711121 - 财政年份:1994
- 资助金额:
$ 20.5万 - 项目类别:
HSV INDUCED RNA DEGRADATION AND PATHOGENESIS
HSV 诱导的 RNA 降解和发病机制
- 批准号:
2888450 - 财政年份:1994
- 资助金额:
$ 20.5万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 20.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 20.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 20.5万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 20.5万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 20.5万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 20.5万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 20.5万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 20.5万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 20.5万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 20.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)